GSK finds healthy take up for triple

Glaxo 230x150 Brentford HQ
By Nigel Owen
07 Sep 2017

On Tuesday, pharmaceutical firm GlaxoSmithKline returned to the corporate bond market for the first time since November 2014, and its rarity value contributed to combined order books of over €5.5bn for the triple tranche deal.

The UK company is rated A2/A+ and its A2 rating from Moody’s was returned to a stable outlook in July. Moody’s had changed the issuer’s outlook to negative in May 2015. However, on July 27, Knut Slatten, a senior analyst at Moody's, said: “The decision to stabilise the ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.